GSK - GSK plc
GSK NYSE: GSK is pursuing a focused oncology expansion built around hematologic malignancies, gynecologic cancers, lung cancer, gastrointestinal cancers and prostate cancer, with a combination of internal research and business development, according to Hesham Abdullah, the company's senior vice president and global head of oncology research and development.
GSK plc (GSK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
GSK's $750M Chimagen deal adds a trispecific TCE to its multiple myeloma portfolio, targeting two tumor antigens simultaneously.
GSK said on Tuesday it had agreed a deal worth up to $750 million to buy a trispecific T cell-engager (TCE), a drug designed to help T-cells target cancer, from China-based biotechnology firm Chimagen Biosciences.
GSK's Jideytro delivers strong first-line NSCLC results, with high response rates and durable disease control supporting a planned FDA filing.
GSK NYSE: GSK is accelerating investment in research and development, expanding its late-stage pipeline and targeting cost savings to support product launches while maintaining profitability through upcoming HIV patent expirations, Chief Financial Officer Julie Brown said during a company discussion.
GSK said on Friday it will be shutting down a vaccine factory in Dresden, Germany, which its website showed produces flu and hepatitis shots, in the summer of 2027.
GSK's Specialty Medicines are driving growth, but an approaching HIV patent cliff is pushing the company to accelerate its pipeline.
GSK plc (GSK) Presents at Bernstein's 23rd Annual Pan-European Strategic Decisions Conference Transcript
GSK PLC's (LSE:GSK, NYSE:GSK) experimental mRNA flu vaccine produced data that closely resemble Moderna's own candidate, according to Deutsche Bank. Analyst Emmanuel Papadakis reviewed detailed phase II results GSK presented at the OPTIONS XIII Conference for the Control of Influenza last weekend.
HUTCHMED NASDAQ: HCM said it has entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted therapy conjugate, or ATTC. The transaction has a total potential value of approximately $1.3 billion, including a $110 million upfront payment, according to Acting Chief Executive Officer and Chief Financial Officer Johnny Cheng.
Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) won ringing endorsements from City brokers on Thursday after securing a blockbuster licensing agreement with GSK PLC (LSE:GSK, NYSE:GSK), exposing what analysts regard as a deep valuation disconnect. The shares leapt 15% to 205.84p as Cavendish and Panmure Liberum reiterated their respective 'buy' ratings, arguing that the market continues to overlook the biotech's expanding oncology pipeline.
Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares jumped 17% to 210p on Thursday after the oncology specialist struck a licensing agreement with GSK worth up to US$1.295 billion for its experimental KRAS-EGFR cancer therapy. The shares were up 30.5p from Wednesday's 179.5p close following news that GSK will receive exclusive rights outside Mainland China, Hong Kong, Macau and Taiwan to develop and commercialise HMPL-A830.
GSK subsidiary GlaxoSmithKline Intellectual Property (No. 4) Ltd will pay a unit of HUTCHMED (China) $110 million upfront for rights to an experimental drug for solid tumours, the Chinese drugmaker said on Thursday.
GSK to advance its mRNA flu vaccine into phase III after phase II study has shown stronger immune responses and good tolerability.
Today's major mRNA headline is a competitive threat to Moderna (NASDAQ:MRNA | MRNA Price Prediction), and the stock is climbing anyway.
GSK's shares are down 14% in six months, but strong Specialty Medicines growth and a robust pipeline may support long-term gains.
GSK said on Tuesday it will advance its mRNA-based seasonal influenza vaccine candidate into a late-stage trial after mid-stage data showed it generated stronger immune responses than currently approved standard- and high-dose shots.
GSK PLC Sponsored ADR (NYSE: GSK - Get Free Report) has received a consensus recommendation of "Hold" from the ten brokerages that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, six have issued a hold rating, one has issued a buy rating and one has issued
H2 2026/Q1 2027 will be rich in catalysts. From the potential FDA approval of bepirovirsen, with a target action date of October 26, for the treatment of chronic hepatitis B, to the Phase 3 OCEAN study results. By the way, Hibsago [bepirovirsen] was approved by Japan's Ministry of Health, Labour, and Welfare on August 24.